Trial · NCT00837330

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

NCT00837330, Phase 1, Phase 2, Completed, Southeast Retina Center, Georgia; results first posted 2014-06-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy. Trials, record NCT00837330. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00837330

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
NCT number: NCT00837330
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Southeast Retina Center, Georgia
Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab 0.5 or 0.3 mg/0.05 cc
First posted: 2009-02-05
Last updated: 2019-04-16
Results first posted: 2014-06-23

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Commonly Reported and Notable Adverse Events	2 years	Incidence and severity of ocular adverse events, as identified by indirect and direct examination. Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more of clinical macula (arcade to arcade), disease-related vitreous hemorrhage, injection-related endopthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Commonly Reported and Notable Adverse Events	2 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group52

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Commonly Reported and Notable Adverse Events	Ranibizumab 0.5 mg	Spider webs	1	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.3 mg	Spider webs	2	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.5 mg	Eye pain, burning	2	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.3 mg	Eye pain, burning	3	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.5 mg	Wavy Lines	1	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.3 mg	Wavy Lines	2	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.5 mg	Seeing Dark spots	2	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.3 mg	Seeing Dark spots	2	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.5 mg	Flashes of Light	1	participants
Commonly Reported and Notable Adverse Events	Ranibizumab 0.3 mg	Flashes of Light	1	participants

1 to 10 of 52Source ClinicalTrials.gov

See all 52 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Intraocular Injection 0.5 mg Ranibizumab	10
Overall Study	STARTED	Intraocular Injection 0.3 mg Ranibizumab	10
Overall Study	COMPLETED	Intraocular Injection 0.5 mg Ranibizumab	9
Overall Study	COMPLETED	Intraocular Injection 0.3 mg Ranibizumab	7
Overall Study	NOT COMPLETED	Intraocular Injection 0.5 mg Ranibizumab	1
Overall Study	NOT COMPLETED	Intraocular Injection 0.3 mg Ranibizumab	3

Source ClinicalTrials.gov

Adverse events44

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Flashes of Light	Eye disorders	Ranibizumab 0.5 mg	1	10	1
other	Flashes of Light	Eye disorders	Ranibizumab 0.3 mg	1	10	1
other	Worsening of Cataract	Eye disorders	Ranibizumab 0.5 mg	1	10	1
other	Worsening of Cataract	Eye disorders	Ranibizumab 0.3 mg	2	10	3
other	Injection Site Pain	Eye disorders	Ranibizumab 0.5 mg	2	10	4
other	Injection Site Pain	Eye disorders	Ranibizumab 0.3 mg	3	10	3
other	Itchy, Watery Eyes	Eye disorders	Ranibizumab 0.5 mg	1	10	1
other	Itchy, Watery Eyes	Eye disorders	Ranibizumab 0.3 mg	2	10	4
other	Vitreous Hemorrhage	Eye disorders	Ranibizumab 0.5 mg	1	10	1
other	Vitreous Hemorrhage	Eye disorders	Ranibizumab 0.3 mg	2	10	2

1 to 10 of 44Source ClinicalTrials.gov

See all 44 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ranibizumab 0.5 mg
Total, all-cause mortality	Ranibizumab 0.3 mg
Total, other adverse events	Ranibizumab 0.5 mg	9	10
Total, other adverse events	Ranibizumab 0.3 mg	8	10
Total, serious adverse events	Ranibizumab 0.5 mg	0	10
Total, serious adverse events	Ranibizumab 0.3 mg	0	10

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22990319	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Ranibizumab 0.5 mg vs Ranibizumab 0.3 mg: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00837330

GET https://conductscience.org/api/trials/v1/NCT00837330/results?page=2

API reference For AI assistants